Back to today’s briefing

Story perspectives

Praxis Stock Soars 200% Amid Epilepsy Program Success

10/17/2025

30 4 Full Breakdown

Summary

Story summary

Praxis Precision Medicines Inc.'s stock has risen nearly 200% after positive developments in its epilepsy programs.
JonesResearch issued a Buy rating with an $83 price target, reflecting confidence in Praxis's potential.
The company posted a net loss of over $71 million in recent quarters while reporting assets above $452 million and a current ratio of 6.3.
Praxis has introduced stock awards for new employees to improve retention.

History

Historical Context

In 2013, the FDA approved Epidiolex, the first cannabis-derived medication for epilepsy, reflecting a shift in treatment paradigms. This approval spurred interest in innovative therapies, leading companies like Praxis Precision Medicines Inc. to see stock surges of nearly 200%. The growing investor confidence, highlighted by JonesResearch's $83 price target, underscores the evolving landscape of the pharmaceutical industry.

1 of 2

Story summary

Praxis Precision Medicines Inc.'s stock has risen nearly 200% after positive developments in its epilepsy programs.
JonesResearch issued a Buy rating with an $83 price target, reflecting confidence in Praxis's potential.
The company posted a net loss of over $71 million in recent quarters while reporting assets above $452 million and a current ratio of 6.3.
Praxis has introduced stock awards for new employees to improve retention.

1 / 2